Fibroblast phenotype in male carriers of FMR1 premutation alleles

D Garcia-Arocena, JE Yang, JR (Jaap) Brouwer, F Tassone, C Iwahashi, EM Berry-Kravis, CG Goetz, AM Sumis, LL Zhou, DV Nguyen, L Campos, E Howell, A Ludwig, C Greco, Rob Willemsen, RJ Hagerman, PJ Hagerman

Research output: Contribution to journalArticleAcademicpeer-review

60 Citations (Scopus)


Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative disorder among carriers of premutation expansions (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene. The clinical features of FXTAS, as well as various forms of clinical involvement in carriers without FXTAS, are thought to arise through a direct toxic gain of function of high levels of FMR1 mRNA containing the expanded CGG repeat. Here we report a cellular endophenotype involving increased stress response (HSP27, HSP70 and CRYAB) and altered lamin A/C expression/organization in cultured skin fibroblasts from 11 male carriers of premutation alleles of the FMR1 gene, including six patients with FXTAS and five premutation carriers with no clinical evidence of FXTAS, compared with six controls. A similar abnormal cellular phenotype was found in CNS tissue from 10 patients with FXTAS. Finally, there is an analogous abnormal cellular distribution of lamin A/C isoforms in knock-in mice bearing the expanded CGG repeat in the murine Fmr1 gene. These alterations are evident even in mouse embryonic fibroblasts, raising the possibility that, in humans, the expanded-repeat mRNA triggers pathogenic mechanisms early in development, thus providing a molecular basis for the neurodevelopmental abnormalities observed in some children and clinical symptoms in some adults who are carriers of premutation FMR1 alleles. Cellular dysregulation in fibroblasts represents a novel and highly advantageous model for investigating disease pathogenesis in premutation carriers and for quantifying and monitoring disease progression. Fibroblast studies may also prove useful in screening and testing the efficacy of therapeutic interventions.
Original languageUndefined/Unknown
Pages (from-to)299-312
Number of pages14
JournalHuman Molecular Genetics
Issue number2
Publication statusPublished - 2010

Research programs

  • EMC MGC-02-96-01

Cite this